Rapid Micro Biosystems (RPID) Expected to Release Earnings on Friday

Rapid Micro Biosystems (NASDAQ:RPID) is anticipated to issue its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Rapid Micro Biosystems to post earnings of ($0.20) per share and revenue of $9.88 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.

Rapid Micro Biosystems (NASDAQ:RPID) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Rapid Micro Biosystems had a negative net margin of 145.56% and a negative return on equity of 177.04%. The business had revenue of $8.05 million during the quarter, compared to analyst estimates of $7.88 million. On average, analysts expect Rapid Micro Biosystems to post ($0.94) EPS for the current fiscal year and ($0.72) EPS for the next fiscal year.

Rapid Micro Biosystems Trading Down 1.5%

NASDAQ RPID opened at $0.69 on Wednesday. The business has a 50 day simple moving average of $1.05 and a 200 day simple moving average of $2.22. Rapid Micro Biosystems has a one year low of $0.65 and a one year high of $4.94. The stock has a market capitalization of $34.71 million, a P/E ratio of -0.62 and a beta of 1.52. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.55 and a quick ratio of 1.51.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on RPID. Roth Capital began coverage on shares of Rapid Micro Biosystems in a research note on Tuesday, September 29th. They issued a “buy” rating and a $3.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $5.00.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc develops automated solutions for microbial quality control in regulated manufacturing environments. Its systems are designed to detect and quantify microorganisms more efficiently than traditional manual methods, helping customers improve testing workflows, data integrity, and laboratory productivity.

The company’s primary platform, Growth Direct, supports applications including environmental monitoring and rapid microbial testing. The platform combines automated incubation, imaging, detection, and reporting with dedicated consumables, enabling pharmaceutical, biotechnology, medical device, and other manufacturers to monitor contamination risks and evaluate product sterility.

Founded in 2006 and headquartered in Lowell, Massachusetts, Rapid Micro Biosystems serves customers in the pharmaceutical and biotechnology industries, as well as other regulated markets such as medical devices and personal care.